Scienture Holdings, Inc. (SCNX) - Net Assets
Based on the latest financial reports, Scienture Holdings, Inc. (SCNX) has net assets worth $70.12 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($84.18 Billion) and total liabilities ($14.06 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Scienture Holdings, Inc. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $70.12 Billion |
| % of Total Assets | 83.3% |
| Annual Growth Rate | 129.64% |
| 5-Year Change | 1859771.79% |
| 10-Year Change | N/A |
| Growth Volatility | 25391.82 |
Scienture Holdings, Inc. - Net Assets Trend (2006–2025)
This chart illustrates how Scienture Holdings, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore Scienture Holdings, Inc. asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Scienture Holdings, Inc. (2006–2025)
The table below shows the annual net assets of Scienture Holdings, Inc. from 2006 to 2025. For live valuation and market cap data, see market cap of Scienture Holdings, Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $70.12 Billion | +88579.02% |
| 2024-12-31 | $79.07 Million | +14479.46% |
| 2023-12-31 | $542.35K | +58.18% |
| 2022-12-31 | $342.87K | -90.91% |
| 2021-12-31 | $3.77 Million | -56.56% |
| 2020-12-31 | $8.68 Million | +109.63% |
| 2019-12-31 | $4.14 Million | +390.16% |
| 2018-12-31 | $844.67K | +370.79% |
| 2017-12-31 | $-311.93K | +72.83% |
| 2016-12-31 | $-1.15 Million | -529.96% |
| 2015-12-31 | $267.02K | -60.05% |
| 2014-12-31 | $668.44K | +410.79% |
| 2013-12-31 | $130.87K | +100.27% |
| 2008-12-31 | $-48.01 Million | -259231.28% |
| 2007-12-31 | $-18.51K | -291.39% |
| 2006-12-31 | $9.67K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scienture Holdings, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8055122757300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $406.00K | 0.00% |
| Other Components | $150.67 Billion | 214.88% |
| Total Equity | $70.12 Billion | 100.00% |
Scienture Holdings, Inc. Competitors by Market Cap
The table below lists competitors of Scienture Holdings, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nusa Palapa Gemilang PT Tbk
JK:NPGF
|
$13.86 Million |
|
Temple Bar Investment Trust
LSE:TMPL
|
$13.87 Million |
|
CSH Alliance Bhd
KLSE:7165
|
$13.87 Million |
|
Oxford Nanopore Technologies Ltd
LSE:ONT
|
$13.88 Million |
|
Surgepays Inc
NASDAQ:SURG
|
$13.85 Million |
|
Yorkton Equity Group Inc
V:YEG
|
$13.85 Million |
|
TS Corp Preference Shares
KO:001795
|
$13.85 Million |
|
Asuransi Dayin Mitra Tbk
JK:ASDM
|
$13.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scienture Holdings, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 79,072,121 to 70,120,384,000, a change of 70,041,311,879 (88579.0%).
- Net loss of 41,512,264,000 reduced equity.
- New share issuances of 26,293,039 increased equity.
- Other factors increased equity by 111,527,282,840.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-41.51 Billion | -59.2% |
| Share Issuances | $26.29 Million | +0.04% |
| Other Changes | $111.53 Billion | +159.05% |
| Total Change | $- | 88579.02% |
Book Value vs Market Value Analysis
This analysis compares Scienture Holdings, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $8.23 | $0.40 | x |
| 2007-12-31 | $-15.76 | $0.40 | x |
| 2008-12-31 | $-40859.57 | $0.40 | x |
| 2013-12-31 | $0.84 | $0.40 | x |
| 2014-12-31 | $2.02 | $0.40 | x |
| 2015-12-31 | $0.77 | $0.40 | x |
| 2016-12-31 | $-3.28 | $0.40 | x |
| 2017-12-31 | $-0.82 | $0.40 | x |
| 2018-12-31 | $2.18 | $0.40 | x |
| 2019-12-31 | $10.47 | $0.40 | x |
| 2020-12-31 | $16.90 | $0.40 | x |
| 2021-12-31 | $6.95 | $0.40 | x |
| 2022-12-31 | $1.35 | $0.40 | x |
| 2023-12-31 | $0.23 | $0.40 | x |
| 2024-12-31 | $21.64 | $0.40 | x |
| 2025-12-31 | $456.89 | $0.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scienture Holdings, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9618025.57%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.20x
- Recent ROE (-59.20%) is above the historical average (-398.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -90.20% | 0.00% | 0.00x | 1.36x | $-9.69K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-26.33K |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.70 Million |
| 2013 | -1598.05% | -218.78% | 2.37x | 3.09x | $-2.10 Million |
| 2014 | -301.01% | -134.47% | 1.22x | 1.83x | $-2.08 Million |
| 2015 | -418.39% | -38.36% | 1.44x | 7.59x | $-1.14 Million |
| 2016 | 0.00% | -111.21% | 7.36x | 0.00x | $-2.65 Million |
| 2017 | 0.00% | 9.86% | 4.75x | 0.00x | $320.18K |
| 2018 | 1.07% | 0.24% | 1.72x | 2.64x | $-75.43K |
| 2019 | -6.87% | -3.82% | 1.33x | 1.35x | $-698.45K |
| 2020 | -29.22% | -14.81% | 1.75x | 1.13x | $-3.40 Million |
| 2021 | -141.00% | -53.75% | 1.72x | 1.53x | $-5.69 Million |
| 2022 | -454.98% | -33.87% | 2.76x | 4.86x | $-3.55 Million |
| 2023 | -3290.03% | -1308.34% | 0.11x | 23.11x | $-17.90 Million |
| 2024 | 11.47% | 6634.66% | 0.00x | 1.33x | $1.16 Million |
| 2025 | -59.20% | -9618025.57% | 0.00x | 1.20x | $-48.52 Billion |
Industry Comparison
This section compares Scienture Holdings, Inc.'s net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $211,993,723
- Average return on equity (ROE) among peers: -14.26%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | $70.12 Billion | -90.20% | 0.20x | $13.86 Million |
| Bimi International Medical Inc (BIMI) | $9.99 Million | -168.11% | 1.31x | $1.40K |
| High Tide Inc (HITI) | $-9.66 Million | 0.00% | 0.00x | $213.45 Million |
| Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) | $4.25 Million | 31.26% | 1.04x | $7.54 Million |
| PetMed Express Inc (PETS) | $85.13 Million | -7.37% | 0.75x | $49.22 Million |
| Ridgetech, Inc. (RDGT) | $22.74 Million | -14.04% | 3.68x | $25.42 Million |
| SunLink Health Systems Inc (SSY) | $9.90 Million | 26.26% | 3.65x | $7.85 Million |
| Walgreens Boots Alliance Inc (WBA) | $1.57 Billion | 17.91% | 0.85x | $10.37 Billion |
| Wellgistics Health, Inc. Common Stock (WGRX) | $-5.25K | 0.00% | 0.00x | $11.07 Million |
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. Th… Read more